scholarly journals Codeine dispensing for privately insured children in the USA: a retrospective database study

2021 ◽  
Vol 5 (1) ◽  
pp. e001321
Author(s):  
Lucas Oliveira J e Silva ◽  
Jana L Anderson ◽  
Fernanda Bellolio ◽  
Ronna L Campbell ◽  
Molly M Jeffery

In this retrospective study using claims data from the OptumLabs Data Warehouse including 24 658 769 eligible person-years of coverage in the USA, there was substantial decline in codeine dispensing between 2010 and 2019. However, we also observed a persistence of codeine prescribing despite the FDA contraindication in 2018. In 2019, codeine was still being prescribed to children aged 12–17 years at 934 prescriptions per 100 000 person-years of coverage and 106 per 100 000 person-years of coverage in children aged<12 years.

2017 ◽  
Vol 76 (2) ◽  
pp. 229-239 ◽  
Author(s):  
Keith D. Lind ◽  
Claire M. Noel-Miller ◽  
Lindsey R. Sangaralingham ◽  
Nilay D. Shah ◽  
Erik P. Hess ◽  
...  

Policy and financial pressures have driven up use of observation stays for patients in traditional Medicare and the Veterans’ Affairs Healthcare System. Using claims data (2004-2014) from OptumLabs™ Data Warehouse, we examined whether people in private Medicare Advantage (MA) and commercial plans experienced similar changes. We found that use of observation increased rapidly for patients in MA plans—even though MA plans were not subject to the same pressures as government-run programs. In contrast, use of observation remained constant for people in commercial plans—except for enrollees 65 and older, for whom it increased somewhat. Privately insured patients returning to the hospital after an inpatient stay were increasingly likely to be placed under observation. Our results suggest that observation is rapidly replacing inpatient admissions and readmissions for many older patients in MA and commercial plans, while younger patients continue to be admitted as inpatients at relatively constant rates.


2019 ◽  
Vol 8 (13) ◽  
pp. 1111-1123 ◽  
Author(s):  
Brooke M Faught ◽  
Graziella Soulban ◽  
Jason Yeaw ◽  
Christiane Maroun ◽  
Katharine Coyle ◽  
...  

Aim: Objective was to compare adherence and persistence, as well as direct healthcare costs and utilization, of ospemifene to available local estrogen therapies (LETs). Patients & methods: This retrospective database study used integrated medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims – US Database. Results: Ospemifene patients had significantly greater adherence and persistence compared with the other nonring LETs. Ospemifene had the lowest mean outpatient costs of any of the LET cohorts, including the estradiol vaginal ring. Total all-cause healthcare costs were also significantly less for ospemifene patients compared with all other LETs.


2006 ◽  
Vol 36 (11) ◽  
pp. 1535-1540 ◽  
Author(s):  
ERIC Q. WU ◽  
LIZHENG SHI ◽  
HOWARD BIRNBAUM ◽  
TERESA HUDSON ◽  
RONALD KESSLER

Background. Schizophrenia is a debilitating chronic mental illness. However, the annual prevalence of schizophrenia is not well understood because of under-representation of schizophrenia patients in epidemiological surveys. This study used multiple administrative claims databases to estimate the annual prevalence of diagnosed schizophrenia in the USA.Method. The annual prevalence of diagnosed schizophrenia in the USA was estimated for different health insurance coverage groups. The prevalence for privately insured individuals was calculated from an administrative claims database of approximately 3 million privately insured beneficiaries covering the period 1999–2003. The prevalence for Medicaid enrollees was calculated from California Medicaid claims covering the period 2000–2002. The prevalence for Medicare and Medicaid/Medicare dual eligibles was estimated using a combination of both databases. Published statistics were used to estimate the prevalence of schizophrenia in the uninsured and veteran populations and to weight the prevalence rates obtained to the population of the USA.Results. The 12-month prevalence of diagnosed schizophrenia in the USA in 2002 was estimated at 5·1 per 1000 lives. The Medicaid population was identified with the highest prevalence rate among the populations studied. Sensitivity analyses taking into consideration the Veterans Affairs population only changed the estimate slightly to 5·3 per 1000 lives.Conclusion. Analyses of administrative claims data contribute to the understanding of the prevalence of diagnosed schizophrenia.


2017 ◽  
Vol 34 (1) ◽  
pp. 117-121 ◽  
Author(s):  
Eleanor O. Caplan ◽  
Pravin S. Kamble ◽  
Raymond A. Harvey ◽  
B. Gabriel Smolarz ◽  
Andrew Renda ◽  
...  

2019 ◽  
Vol 6 (2) ◽  
pp. 140-150 ◽  
Author(s):  
Helen J Curtis ◽  
Richard Croker ◽  
Alex J Walker ◽  
Georgia C Richards ◽  
Jane Quinlan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document